Company profile for Acrivon Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform. Our method is widely applicable across drug classes and modalities. We specifically apply our approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single gene driver mutations or synthetic lethal contex...
Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform. Our method is widely applicable across drug classes and modalities. We specifically apply our approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single gene driver mutations or synthetic lethal contexts. Leveraging our unique patient selection platform, Acrivon Therapeutics aims to rapidly progress in-licensed clinical-stage assets and a pipeline of internally developed programs

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Watertown, MA, USA 480 Arsenal Way Suite 100 Watertown, MA 02472
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://ir.acrivon.com/news-releases/news-release-details/acrivon-therapeutics-reports-initial-positive-clinical-data-acr

PRESS RELEASE
24 Apr 2024

https://ir.acrivon.com/news-releases/news-release-details/acrivon-therapeutics-host-corporate-rd-event-highlighting-ap3

PRESS RELEASE
16 Apr 2024

https://ir.acrivon.com/news-releases/news-release-details/acrivon-therapeutics-presents-data-aacr-annual-meeting

PRESS RELEASE
10 Apr 2024

https://ir.acrivon.com/news-releases/news-release-details/acrivon-therapeutics-announces-130-million-private-placement

PRESS RELAESE
09 Apr 2024

https://www.biopharmadive.com/news/acrivon-ipo-file-biotech-cancer-lilly/634468/

BIOPHARMADIVE
19 Oct 2022

https://www.globenewswire.com/news-release/2022/06/28/2470336/0/en/Akoya-Biosciences-to-Partner-with-Acrivon-Therapeutics-for-the-Clinical-Development-of-Acrivon-s-Proprietary-OncoSignature-Test-into-a-Companion-Diagnostic.html

GLOBENEWSWIRE
28 Jun 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty